Introduction
The regulation of gene splicing in neurons (reviewed in Li et al. [1] ), particularly during development, appears to be an important mechanism for controlling expression of genes key to histogenic processes. Splicing results in multiple protein products arising from a single gene locus, based on specific exon splicing. Exon usage in the nervous system varies by cell type, developmental stage, and can be regulated by activity [1] . The full dynamic range of alternative splicing mechanisms of genes expressed in neurons is unclear, but there are significant pathophysiological consequences of a disruption in the ability to splice [2] .
Ataxin-2-binding protein 1 (A2BP1) is a neuronal splicing regulator necessary for proper exon usage in several mammalian genes with tissue-specific splice variants, such as exon EIIIB inclusion in fibronectin [3, 4] , calcitonin/calcitonin gene-related peptide [5] , CaV1.2 voltage-gated calcium channels [6] and NMDA receptor 1 [7] . Gene disruption of A2BP1 has been associated with a variety of neurodevelopmentally based brain disorders, including autism [8] [9] [10] , mental retardation with epilepsy [11] , attention deficit hyperactivity disorder [12] and schizophrenia [13, 14] .
Mammalian A2bp1 was first identified by Shibata et al. [15] in a yeast two-hybrid screen for interacting partners of ataxin-2, which is disrupted in spinocerebellar ataxia type 2. Three isoforms of A2BP1 were identified in postmortem adult human brain by Northern blot [15] . A 4.4-kb isoform was most predominantly expressed in the cerebellum, while 2 less abundant isoforms (3.4 and 6.2 kb) were expressed in the cerebral cortex and putamen [15] . In mice, this highly conserved RNA-binding protein also shows expression in the brain by Northern blot analysis and immunocytochemistry [16] . As in the human central nervous system, in the mouse brain, there are 3 mRNA isoforms by Northern blot analysis (6.2, 4.0 and 3.4 kb).
A2BP1 has been identified in adult mouse brain by immunohistochemistry. Abundant protein expression in neuronal nuclei exists throughout the adult brain including the hippocampus, cortex, cerebellum and olfactory bulb [4] . There are no detailed in situ hybridization studies or database entries to date of developmental expression of A2bp1, which is somewhat surprising given the functional importance of splicing regulation during brain development, and implications of A2BP1 involvement in neurodevelopmental disorders. In this report, we describe the developmental expression of a transcript from the A2bp1 locus in C57BL6J mouse, characterizing mRNA localization in the forebrain from early stages of neuron production (E11.5) through eye opening (P14).
Materials and Methods

Mouse Care and Use
Timed pregnant C57BL6J mice were bred in-house under protocols approved by the Institutional Animal Care and Use Committee of Vanderbilt University. Mice were maintained on a 12-hour light/12-hour dark cycle and were permitted food and water ad libitum. Noon on the day following a time-delimited overnight pairing was considered E0.5. Pregnant females were deeply anesthetized with isofluorane vapors followed by rapid decapitation in order to harvest fetuses for in situ hybridization. Crown-rump length and external physical features were used to verify fetal ages.
Riboprobe Labeling
An A2bp1 I.M.A.G.E clone (6821627) was obtained from ATCC (Manassas, Va., USA). Informatics analysis indicates that the synthesized probe binds to the large exon in the 3 UTR which is present in two transcript variants. These transcripts encode an A2BP1 protein that terminates in the amino acids FAPY. BLASTing mouse refseq and non-refseq RNA databases with the generated probe did not yield significant homology to other mouse sequences. A transcript from the A2bp1 locus has been mapped in C57BL/6 mouse at one age (E14.5) in the sagittal plane on www.
genepaint.org. The probe in those studies only recognizes transcript variant 2. The identity of the I.M.A.G.E. clone was confirmed by sequencing at the Vanderbilt DNA Sequencing Facility. The clone was linearized with Sal I and transcribed using T3 polymerase (Promega) in a 20-l reaction. Digoxigenin-11-uridine-5 -triphosphate (350 M ; Roche, Indianapolis, Ind., USA) was included in the transcription reaction to allow for non-radioactive colorimetric detection of transcripts. Hydrolyzed and non-hydrolyzed probes yielded the same results. Based on gel electrophoresis of the probe, the overwhelming majority of hydrolyzed products were between 650 and 1,650 nucleotides in length. The images in this report are all from non-hydrolyzed probes.
In situ Hybridization
Fetuses were harvested into cold PBS and whole heads or microdissected brains were immersion fixed for 24 h in 4% formaldehyde made from 4% paraformaldehyde by weight in alkaline water heated to 60 ° C in 0.156 M NaH 2 PO 4 , 0.107 M NaOH, pH 7.12 with HCl. After fixation, brains were cryoprotected in graded 10, 20 and 30% sucrose in PBS followed by embedding in TFM tissue freezing medium (Triangle Biomedical Sciences, Inc., Durham, N.C., USA) over liquid nitrogen vapors. Brains were stored at -80 ° C until sectioning into 6 series at 20 M in a cryostat. Cut sections were stored at -80 ° C until they were fixed, acetylated and dehydrated. After this step, they were returned to -80 ° C until processed for in situ hybridization. The in situ hybridization was performed on a Tecan Evo 150 (Tecan Group Ltd., Männedorf, Switzerland) following the Allen Brain Atlas (http://www.brainmap.org/) and Genepaint (http://www.genepaint.org/) protocols. After completion of the Tecan-run protocol, BCIP and NBT (Roche) were applied manually. The time in color development was 40 min for embryonic tissue and 3 h for P14. After color development, the slides were rinsed 4 times with double distilled water and then twice with 4% formaldehyde, dehydrated through a series of alcohols and coverslipped with VectaMount (Vector Laboratories, Burlingame, Calif., USA). Two cases per age were tested. A sense control probe generated from the same I.M.A.G.E. clone was tested at E14.5 and P14.
Light Microscopy
Images of the rostrocaudal extent of the prenatal material were obtained on an Ariol SL-50 automated imaging platform at ! 10 in the Epithelial Biology Center Imaging Resource Core of Vanderbilt University. Images of the rostrocaudal extent of the P14 material were captured on an Olympus SZX12 microscope. Additional images illustrating higher magnification or comparison across multiple ages were captured on a Zeiss Axioplan with a high-resolution color camera. Any images appearing in the same figure together were captured with a single microscope in the same image capture session, and resulting images underwent the same manipulations for brightness and contrast. Anatomical references were made using an embryonic mouse brain atlas [17] .
Western Blotting
Protein was harvested from 5 different ages of wild-type mice on a C57BL6J background. The dorsal telencephalon/cortex was dissected and nuclear and cytoplasmic fractions were prepared. Twenty micrograms of protein was loaded on a Nupage 4-12% Bis/Tris gel (Invitrogen, Carlsbad, Calif., USA) run for 1.5 h at 140 V and transferred to nitrocellulose at 15 V for 40 min. The blot was incubated in 1: 100 anti-Fox-1 (sc-135476; Santa Cruz Biotechnology, Inc., Santa Cruz, Calif., USA) in 0.5% casein, 0.05% Tween-20 in PBS. After washes in PBS, the blot was incubated in goat anti-rabbit IgG-HRP (GE Healthcare, Piscataway, N.J., USA) at a final concentration of 1: 20,000 and was detected with Super Signal Dura ECL (Pierce/Thermo-Fisher Scientific, Inc., Rockford, Ill., USA).
Results
In situ Hybridization Mapping of Mouse A2bp1
We have characterized A2bp1 expression in prenatal and P14 mouse brain using a probe that recognizes two characterized mRNA transcripts of the A2bp1 locus ( fig. 1 ). At all ages examined prenatally, A2bp1 mRNA detection was evident only in regions containing postmitotic cells. Thus, proliferative zones lining the ventricles throughout the forebrain were unlabeled. Labeling intensity of individual cells was similar at each age. Early pools of postmitotic cells were darkly labeled. Later pools of postmitotic cells (perhaps glia) were unlabeled. This gave the appearance of a lighter label at P14. A sense probe tested at E14.5 and P14 demonstrated the specificity of the anti-sense label (data not shown).
A2bp1 mRNA was detected by in situ hybridization in a small number of cells at E11.5, the earliest time point that we assessed ( fig. 2 ). In particular, the pattern of expression resembled the distribution of postmitotic cells at the cortical plate-mantle region at the early corticostriatal boundary. Labeled cells are evident in the geniculate pretectum and hypothalamus. At this age, there were no labeled cells in the dorsal pallium. Outside of the forebrain, caudally, there was A2bp1 signal in the medullary ventral motor column as well as the ventral spinal cord. By E12.5, the expression of A2bp1 was much more robust ( fig. 3 ) and tracked closely with the known emergence of interneurons arising from the lateral ganglionic eminence (LGE). Transcript-expressing cells were not seen emerging from the medial ganglionic eminence, which gives rise to the majority of parvalbumin cortical interneurons, or within the developing striatum, which contains long-projecting GABAergic neurons. Rather, at this early age, more ventral and posterior areas contained A2bp1 -expressing cells, including the preoptic differentiating zone, the anterobasal nucleus and the lateral hypothalamus. Outside of the forebrain, in the rhombencephalon, there was labeling in the region generating the facial motor nucleus, the ventral pontine differentiating zone and the medullary differentiating zone, the principal sensory trigeminal nucleus and the pontine reticular formation. Outside of the central nervous system, there was emerging labeling in the trigeminal ganglion V and vestibulocochlear ganglion VIII (not depicted). Although dorsal pallial neurons are being produced by this age, and there is a transition from preplate to cortical plate, this dorsal forebrain region remains A2bp1 negative.
By E13.5 ( fig. 4 ) , there continued to be robust A2bp1 expression in cells differentiating in the same areas evident at earlier ages, including those that have migrated from the LGE, hypothalamic and brain stem nuclei. There also was the first appearance of A2bp1-positive cells in the most lateral regions of the dorsal pallium. This timing is coincident with the major increase in neurons populating the developing cortical plate. At this age, there was an abundance of A2bp1 cells residing in the lateral migratory stream from the ganglionic eminence, coincident with the increase in cortical interneuron migration [18] . Labeled neurons in the lateral septum, bed nucleus clone is more similar to transcript variant 2, but identical to both transcript variants 1 and 2 in the large 3 exon, which is the region of the clone that includes the probe that was generated in this study. Although there are other known A2bp1 splice variants, when BLASTing for mRNA hits in NCBI databases with the probe, these are the only two transcripts retrieved. Both of these transcripts encode an A2bp1 isoform which ends in amino acids FAPY. Vertical lines indicate exon boundaries. Asterisks denote transcript-specific exon usage. The shaded region represents the coding region.
of the stria terminalis, amygdala and the preoptic and ventromedial hypothalamus also emerged at this age. Labeling was also seen in the dorsal thalamus. By E14.5 ( fig. 5 ), all lateromedial aspects of the dorsal pallium contained neurons expressing A2bp1 in the cortical plate. Transcript-expressing cells were evident in the striatum distal to the ganglionic eminence. Labeled cells also accumulated in lateral regions of the basal forebrain that include the nascent amygdala. At E15.5-E18.5 (see online supplementary figures 1-4, www. karger.com/doi/10.1159/000323732), expression continued to be excluded from progenitor zones, while labeled cells were abundant in several postmitotic differentiated telencephalic, diencephalic, mesencephalic and rhombencephalic areas.
By the end of the second postnatal week, the expression of A2bp1 became easier to detect in discrete areas ( fig. 6 ). There were many brain areas that retained high levels of expression including the olfactory bulb, nucleus accumbens, thalamus, cortex, hippocampus and striatum to indicate a few. At this age, there were several brain areas that emerged with no signal for this transcript including the ventral pallidum, globus pallidus, habenula, and the ventral tegmentum, which includes the ventral tegmental area and the substantia nigra. At low magnification, A2bp1 expression appeared to be lighter at P14 than at the late prenatal ages (online suppl. figures 1-4). This age difference was likely related to the postnatal emergence of non-neuronal cells that remain unlabeled and does not indicate a decrease of expression in postnatal development. Indeed, at higher magnification ( fig. 7 ) , the distribution and intensity of expression across multiple brain regions looked very similar between P14 and E18.5. At both ages, there was expression in a wide variety of brain regions, including the anterior hypothalamus, the amygdala, the hippocampus and the cortical plate/ neocortex. The two ages also shared a noticeable lack of labeling in some brain regions such as the globus pallidus and ventral pallidum. The main difference between these two ages was that there were more cells at P14 that do not contain A2bp1 . These were potentially glia as they develop later and specifically do not express A2bp1 . At all of the examined ages, the A2bp1 expression was excluded from proliferative zones and was highly restricted to regions that are known to posses differentiated cells ( fig. 8 ) . We observed no expression in the ventricular zone of the dorsal pallium in the medial or LGE. A2bp1 -positive cells were not yet evident in the cortical plate at E12.5 ( fig. 8 a) , but were easily detected in the cortical plate at E13.5 ( fig. 8 b, c) . At E13.5, A2bp1 -positive cells were also evident in the lateral migratory stream. Labeling at E15.5 ( fig. 8 d) was highly consistent with labeling in postmitotic cells. There was no labeling detected in the proliferating cells of the ventricular zone, and modest labeling in the subventricular zone. The majority of the label at this age was in the cortical plate. Based on this labeling pattern at these ages, it is possible that A2bp1 marks populations of postmitotic tangentially migrating interneurons as well as radially migrating projection neurons.
At several pre-and postnatal ages, A2BP1 protein in the dorsal telencephalon/neocortex was detectable by Western blotting ( fig. 9 ) . A distinct band at approximately 43 kDa was apparent at all ages examined and it was evident in both nuclear and cytoplasmic fractions.
Discussion
In this report, we describe the prenatal and early postnatal expression profile of A2bp1 . The data demonstrate that the gene, which serves as a transcriptional splicing factor, is expressed in a developmentally restricted pattern along the neuroaxis that excludes mitotically active cells. A2BP1 was also evident in the forebrain as detected by Western blotting, demonstrating that the mRNA labeled in this study is likely of functional relevance. The clinical implications of mutations in A2bp1 increasing risk for neurodevelopmental disorders including autism, attention deficit hyperactivity disorder, epilepsy and schizophrenia are consistent with the expression patterns in specific regions of the basal forebrain, hippocampus and neocortex. While the expression of A2bp1 became more evident in dorsal pallial regions later in fetal development, the early expression of A2bp1 is consistent with a role in both postmitotic projection neuron and interneuron development. The mapping of A2bp1 in the fetal brain establishes an important dataset for deciphering the potential regulation of downstream target genes. Remarkably, there have been a number of recent analyses addressing potential target genes of A2bp1 regulation with little knowledge of spatiotemporal expression patterns during brain development. For example, Zhang et al. [19] used a bioinformatic approach to identify all of the potential targets of A2BP1 that may contain the conserved splicing motif UGCAUG. Of these genes, several known genes in interneuron specification were listed, including Cutl1 -a gene that includes two known protein products: CASP and Cut1. Other targets of A2BP1 of neurodevelopmental relevance are the activity-dependent alternative splicing of CaV1.2 L-type calcium channels [6] and NMDA receptor 1 [7] . In addition to regulating the alternative splicing of other transcripts, A2bp1 appears to have the potential to self-regulate. Zhang et al. [19] also report that the OMIM database is enriched for genes that contain the UGCAUG recognition motif. Many of the genes in OMIM that contain this recognition motif are associated with epilepsy and a variety of neurodevelopmental disorders including autism, Asperger's syndrome, Rett syndrome, X-linked mental retardation, lissencephaly and schizophrenia. It is important to note that the analysis by Zhang et al. [19] does not distinguish between A2BP1 (FOX1)-specific targets and RBM9 (FOX2)-specific targets, which will be necessary to determine precisely the gene-regulatory targets in A2bp1 -expressing cells during fetal brain development. An additional informatics report, based on a metaanalysis combining GWAS data, functional studies from animal models, and tissue markers from postmortem samples [20] , ranked A2BP1 as the fifth of 41 top candidates to pursue in bipolar disorder. Given the expression pattern of A2bp1, its role in neuronal splicing (and perhaps even sex-steroid-dependent splicing) and its chromosomal position in a highly replicated locus for ASD genome association studies, A2BP1 is a promising candidate for future studies of the molecular etiology of a broad range of neurodevelopmental disorders. Given the large number of UGCAUG sites in the genome and the robust expression from the A2bp1 locus evident in selective neuronal populations in the developing fetal mouse brain, experimental disruption of A2BP1 activity may reveal cell type-specific target genes that lead to clinically relevant dysregulated phenotypes. 
